Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly and Company (NYSE:LLY), a global pharmaceutical giant with a market capitalization of $700 billion, has been at the forefront of innovation in the biopharmaceutical industry ...

Fool.com contributor Parkev Tatevosian discusses the prospects for Eli Lilly stock. *Stock prices used were the afternoon prices of June 14, 2024. The video was published on June 16, 2024.

Technical analysis and Wall Street Ratings of Eli Lilly stock vs. Novo Nordisk stock Based on the parameter values that I have noted in the table below, I believe that Novo Nordisk is a more ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $875.00. Mohit Bansal has given his Buy rating due to a ...

Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year. It has also upgraded its guidance.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.